346 related articles for article (PubMed ID: 23188436)
41. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.
Collins LC; Marotti JD; Gelber S; Cole K; Ruddy K; Kereakoglow S; Brachtel EF; Schapira L; Come SE; Winer EP; Partridge AH
Breast Cancer Res Treat; 2012 Feb; 131(3):1061-6. PubMed ID: 22080245
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
43. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
44. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
[TBL] [Abstract][Full Text] [Related]
45. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
[TBL] [Abstract][Full Text] [Related]
46. [Expression of androgen receptor in breast carcinoma and its relationship with estrogen receptor, progesterone receptor and HER2 status].
Chen J; Zhang X; Tian R; Liu Y; Dong HM; Guo RF; Liang HY
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):743-6. PubMed ID: 21215164
[TBL] [Abstract][Full Text] [Related]
47. [Mammographic and pathological features of triple-negative breast cancer].
Wen SY; Han YW; Ma XM; Zhang J; Cui WJ; Cao XC; Wang X
Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):291-5. PubMed ID: 22781043
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of biomarkers in multifocal/multicentric invasive breast carcinomas.
Pekmezci M; Szpaderska A; Osipo C; Erşahin Ç
Int J Surg Pathol; 2013 Apr; 21(2):126-32. PubMed ID: 23204031
[TBL] [Abstract][Full Text] [Related]
49. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.
Tsang JY; Hui SW; Ni YB; Chan SK; Yamaguchi R; Kwong A; Law BK; Tse GM
Breast Cancer Res Treat; 2014 Jan; 143(1):1-9. PubMed ID: 24272079
[TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical Expression Of Matrix Metalloproteinase-1 (MMP-1) in Different Types Of Breast Carcinoma And Its Comparison With ER/PER and HER2/neu.
Shamsi FB; Anwar A; Lail RA; Bukhari MH; Naseem N; Nagi AH
J Ayub Med Coll Abbottabad; 2022; 34(1):12-16. PubMed ID: 35466619
[TBL] [Abstract][Full Text] [Related]
51. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
Nwafor CC; Keshinro SO
Niger J Clin Pract; 2015; 18(4):553-8. PubMed ID: 25966732
[TBL] [Abstract][Full Text] [Related]
52. HER2-positive breast cancer patients: correlation between mammographic and pathological findings.
Radenkovic S; Konjevic G; Isakovic A; Stevanovic P; Gopcevic K; Jurisic V
Radiat Prot Dosimetry; 2014 Nov; 162(1-2):125-8. PubMed ID: 25063784
[TBL] [Abstract][Full Text] [Related]
53. [Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].
Liu RB; Zhou XH; Wang JN; Liang HZ; Li XX; Wu ZH; Ye JL; Wang SM
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3397-400. PubMed ID: 19159568
[TBL] [Abstract][Full Text] [Related]
54. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
[TBL] [Abstract][Full Text] [Related]
55. Lymphatic vascularization in primary breast cancer: HER2 overexpressing tumors contain more lymphatics than steroid receptor positive, triple-positive and triple negative breast carcinomas.
Popovska S; Ivanov I
Turk Patoloji Derg; 2014; 30(2):124-32. PubMed ID: 24782302
[TBL] [Abstract][Full Text] [Related]
56. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
Sheikh UN; Cohen C; Siddiqui MT
Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
[TBL] [Abstract][Full Text] [Related]
57. Cutaneous metastases from breast carcinoma: calretinin expression and estrogen, progesterone and Her2/neu status of the metastases, compared to primary cutaneous apocrine tumors.
Fernandez-Flores A
Rom J Morphol Embryol; 2013; 54(3 Suppl):695-9. PubMed ID: 24322014
[TBL] [Abstract][Full Text] [Related]
58. Pathology of Senegalese breast cancers.
Fitzpatrick MB; Rendi MH; Kiviat NB; Toure P; Dem A; Sow PS; Hawes SE; Feng Q; Allison KH
Pan Afr Med J; 2019; 34():67. PubMed ID: 31819783
[TBL] [Abstract][Full Text] [Related]
59. Association between mammographic density and basal-like and luminal A breast cancer subtypes.
Razzaghi H; Troester MA; Gierach GL; Olshan AF; Yankaskas BC; Millikan RC
Breast Cancer Res; 2013; 15(5):R76. PubMed ID: 24008056
[TBL] [Abstract][Full Text] [Related]
60. Mammographic features are associated with clinicopathological characteristics in invasive breast cancer.
Jiang L; Ma T; Moran MS; Kong X; Li X; Haffty BG; Yang Q
Anticancer Res; 2011 Jun; 31(6):2327-34. PubMed ID: 21737659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
